Erika Ross, Director of Clinical & Applied Research at Abbott Shares Insights on FDA Breakthrough Device Designation to Explore its DBS System to Treat Treatment-Resistant Depression

Shots: Erika spoke about the FDA Breakthrough Device Designation received by Abbott to investigate its deep brain stimulation (DBS) system to treat treatment-resistant depression (TRD)Erika also talked about how NeuroSphere Virtual Clinic is compatible with the  deep brain stimulation (DBS) system The interview gives an understanding of Abbott’s vision to bring life-changing technologies in…